LIGANDS FOR ANTIBODY PURIFICATION BY AFFINITY CHROMATOGRAPHY

摘要

The present invention relates to the use, for affinity purification of a protein, of a compound according to the general formula (I), wherein A is selected from the group: -O-;-S-; >CR7R8; and NR9; D is a linear or branched Ci to C6 alkyl group, which may comprise a cycloalkyl unit, wherein 1 or more C-atoms which are not connected to each other may be replaced by O or S, and wherein one or more C-atoms in the alkyl group may be substituted by one or more atoms independently from each other selected from the group F, C1, Br, I; L is the linking point via which the compound is attached to a support matrix, L optionally comprising a spacer group -Z-; R1, R2 are identical or different and are independently of each other selected from the group: H; -OH; linear and branched C1 to C4 alkyl, which may comprise a cycloalkyl unit; wherein in the alkyl 1 C-atom may be replaced by -O-, or a terminal C-atom may be replaced by -OH; wherein N may be part of a heterocycle having 3 to 7 members; and wherein one or more C- atoms in the alkyl may be substituted by one or more atoms independently from each other selected from the group F, C1, Br, I; R3, R4, R5 and R6 are identical or different and are independently of each other selected from the group: H; linear and branched C1 to C4 alkyl, which may comprise a cycloalkyl unit, and wherein in the alkyl 1 C-atom may be replaced by -0-, or a terminal C-atom may be replaced by -OH; and wherein one or more C-atoms in each R3, R4, R5 and R6 may be substituted by one or more atoms independently from each other selected from the group F, C1, Br, I; and - NR10R11; R7, R8 are identical or different and are selected from the group: H; linear and branched C1 to C4 alkyl, which may comprise a cycloalkyl unit, wherein the alkyl group may optionally be substituted; R9 is selected from the group: H; linear and branched C1 to C4 alkyl, which may comprise a cycloalkyl unit, and wherein the alkyl group may optionally be substituted; R10, R11 can be identical or different and are independently of each other selected from the group: H; linear and branched C1 to C4 alkyl, which may comprise a cycloalkyl unit, and wherein the alkyl group may optionally be substituted. Preferably, the entity to be separated of purified is an antibody, in particular an antibody of the Bevacizumab type or the Ranibizumab type.